Trigeminal-Targeted Treatments in Migraine: Is 60% the Magic Number?

Piero Barbanti, Gabriella Egeo, Dimos D. Mitsikostas

Research output: Contribution to journalArticlepeer-review


Trigeminal-targeted treatments (TTTs), the most specific and selective therapeutic migraine approach to date, are effective in approximately 60% of patients regardless of treatment type or mechanism, at least if used alone. Sixty percent is also the proportion of migraineurs who develop migraine-like episodes following experimental intravenous administration of trigeminal neuropeptides and roughly 60% is the percentage of patients with a unilateral migraine tracing the area of cutaneous distribution of the trigeminal ophthalmic branch. Hence, mechanisms other than the trigeminovascular activation are probably involved in the 40% of migraineurs who do not respond to TTTs. A closer cooperation between clinical and basic neuroscientists is needed to explore migraine models because only a careful appraisal of migraine endophenotypes may help to unravel their underlying multifaceted pathophysiological machinery.

Original languageEnglish
Pages (from-to)1659-1661
Number of pages3
Issue number9
Publication statusPublished - Oct 1 2019


  • botulinum toxin
  • calcitonin gene-related peptide antibodies
  • endophenotype
  • gepant
  • migraine
  • treatment
  • triptan

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Trigeminal-Targeted Treatments in Migraine: Is 60% the Magic Number?'. Together they form a unique fingerprint.

Cite this